Immunovant, Inc. (NasdaqGS: IMVT)
Health Care · Biotechnology · US
$30.47
+0.69% today · +74.3% 1Y
Immunovant, Inc. (NasdaqGS: IMVT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.29B and employs 315 people.
Over the last twelve months the share price has gained 74.3%, trading between 15.95 and 45.42.
Tweenvest scores Immunovant, Inc. across four factors: quality 36/100, value 59/100. Its strongest factor is value.
IMVT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.29B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.82
- Dividend yield
- —
- Beta (5Y)
- 0.84
- 52-week high
- $45.42
- 52-week low
- $15.95
- Avg volume (3M)
- —
- Shares outstanding
- 206.55M
- Employees
- 315
- Next earnings
- —
About Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
- ISIN
- US45258J1025
- Founded
- 2018
- Listed since
- Jun 21, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd.SEHK: 2315 | $6.75B | HK$69.20 | +2.59% |
| Gan & Lee Pharmaceuticals.SHSE: 603087 | $6.71B | CN¥75.52 | -2.43% |
| Iovance Biotherapeutics, Inc.NasdaqGM: IOVA | $6.62B | $14.62 | +9.84% |
| Grifols, S.A.BME: GRF | $6.62B | €9.88 | +2.02% |
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $140.58 | +6.01% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $99.87 | +5.74% |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $90.78 | -2.21% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $79.78 | +1.31% |
Figures last refreshed Oct 11, 2026.